|
1
|
Linehan WM: The genetic basis of kidney
cancer: Implications for management and use of targeted therapeutic
approaches. Eur Urol. 61:896–898. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nerich V, Hugues M, Paillard MJ, Borowski
L, Nai T, Stein U, Nguyen Tan Hon T, Montcuquet P, Maurina T,
Mouillet G, et al: Clinical impact of targeted therapies in
patients with metastatic clear-cell renal cell carcinoma. Onco
Targets Ther. 7:365–374. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Meloni-Ehrig AM: Renal cancer: Cytogenetic
and molecular genetic aspects. Am J Med Genet. 115:164–172. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheville JC, Lohse CM, Zincke H, Weaver AL
and Blute ML: Comparisons of outcome and prognostic features among
histologic subtypes of renal cell carcinoma. Am J Surg Pathol.
27:612–624. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rini BI, Rathmell WK and Godley P: Renal
cell carcinoma. Curr Opin Oncol. 20:300–306. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ljungberg B, Bensalah K, Canfield S,
Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L,
Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014
update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Albiges L, Choueiri T, Escudier B, Galsky
M, George D, Hofmann F, Lam T, Motzer R, Mulders P, Porta C, et al:
A systematic review of sequencing and combinations of systemic
therapy in metastatic renal cancer. Eur Urol. 67:100–110. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu D, Li M, Wang L, Zhou Y, Zhou J, Pan H
and Qu P: MicroRNA-145 inhibits cell proliferation, migration and
invasion by targeting matrix metallopeptidase-11 in renal cell
carcinoma. Mol Med Rep. 10:393–398. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ha M and Kim VN: Regulation of microRNA
biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kurozumi A, Goto Y, Okato A, Ichikawa T
and Seki N: Aberrantly expressed microRNAs in bladder cancer and
renal cell carcinoma. J Hum Genet. 62:49–56. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vannini I, Fanini F and Fabbri M: Emerging
roles of microRNAs in cancer. Curr Opin Genet Dev. 48:128–133.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lou W, Liu J, Gao Y, Zhong G, Chen D, Shen
J, Bao C, Xu L, Pan J, Cheng J, et al: MicroRNAs in cancer
metastasis and angiogenesis. Oncotarget. 8:115787–115802. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Niu S, Ma X, Zhang Y, Liu YN, Chen X, Gong
H, Yao Y, Liu K and Zhang X: MicroRNA-19a and microRNA-19b promote
the malignancy of clear cell renal cell carcinoma through targeting
the tumor suppressor RhoB. PLoS One. 13:e01927902018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fujii N, Hirata H, Ueno K, Mori J, Oka S,
Shimizu K, Kawai Y, Inoue R, Yamamoto Y, Matsumoto H, et al:
Extracellular miR-224 as a prognostic marker for clear cell renal
cell carcinoma. Oncotarget. 8:109877–109888. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yoshino H, Yonezawa T, Yonemori M,
Miyamoto K, Sakaguchi T, Sugita S, Osako Y, Tatarano S, Nakagawa M
and Enokida H: Downregulation of microRNA-1274a induces cell
apoptosis through regulation of BMPR1B in clear cell renal cell
carcinoma. Oncol Rep. 39:173–181. 2018.PubMed/NCBI
|
|
19
|
Yang F, Ma J, Tang Q, Zhang W, Fu Q, Sun
J, Wang H and Song B: MicroRNA-543 promotes the proliferation and
invasion of clear cell renal cell carcinoma cells by targeting
Krüppel-like factor 6. Biomed Pharmacother. 97:616–623. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang C, Cai L, Liu J, Wang G, Li H, Wang
X, Xu W, Ren M, Feng L, Liu P and Zhang C: MicroRNA-30a-5p inhibits
the growth of renal cell carcinoma by modulating GRP78 expression.
Cell Physiol Biochem. 43:2405–2419. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fu H, Song W, Chen X, Guo T, Duan B, Wang
X, Tang Y, Huang L and Zhang C: miRNA-200a induce cell apoptosis in
renal cell carcinoma by directly targeting SIRT1. Mol Cell Biochem.
437:143–152. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Song H, Rao Y, Zhang G and Kong X:
MicroRNA-384 inhibits the growth and invasion of renal cell
carcinoma cells by targeting astrocyte elevated gene 1. Oncol Res.
26:457–466. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang X, Zhang M, Cheng J, Lv Z, Wang F
and Cai Z: miR-411 functions as a tumor suppressor in renal cell
cancer. Int J Biol Markers. 32:e454–e460. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He YH, Chen C and Shi Z: The biological
roles and clinical implications of microRNAs in clear cell renal
cell carcinoma. J Cell Physiol. 233:4458–4465. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liang S, Zhang N, Deng Y, Chen L, Zhang Y,
Zheng Z, Luo W, Lv Z, Li S and Xun T: Increased serum level of
MicroRNA-663 is correlated with poor prognosis of patients with
nasopharyngeal carcinoma. Dis Markers. 2016:76482152016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liang S, Zhang N, Deng Y, Chen L, Zhang Y,
Zheng Z, Luo W, Lv Z, Li S and Xu T: miR-663 promotes NPC cell
proliferation by directly targeting CDKN2A. Mol Med Rep.
16:4863–4870. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu ZY, Zhang GL, Wang MM, Xiong YN and
Cui HQ: MicroRNA-663 targets TGFB1 and regulates lung cancer
proliferation. Asian Pac J Cancer Prev. 12:2819–2823.
2011.PubMed/NCBI
|
|
28
|
Jiao L, Deng Z, Xu C, Yu Y, Li Y, Yang C,
Chen J, Liu Z, Huang G, Li LC and Sun Y: miR-663 induces
castration-resistant prostate cancer transformation and predicts
clinical recurrence. J Cell Physiol. 229:834–844. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Z, Zhang H, Zhang P, Dong W and He L:
MicroRNA-663 suppresses cell invasion and migration by targeting
transforming growth factor beta 1 in papillary thyroid carcinoma.
Tumour Biol. 37:7633–7644. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zang W, Wang Y, Wang T, Du Y, Chen X, Li M
and Zhao G: miR-663 attenuates tumor growth and invasiveness by
targeting eEF1A2 in pancreatic cancer. Mol Cancer. 14:372015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pan J, Hu H, Zhou Z, Sun L, Peng L, Yu L,
Sun L, Liu J, Yang Z and Ran Y: Tumor-suppressive mir-663 gene
induces mitotic catastrophe growth arrest in human gastric cancer
cells. Oncol Rep. 24:105–112. 2010.PubMed/NCBI
|
|
32
|
Bokoch GM: Biology of the p21-activated
kinases. Annu Rev Biochem. 72:743–781. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Song B, Wang W, Zheng Y, Yang J and Xu Z:
P21-activated kinase 1 and 4 were associated with colorectal cancer
metastasis and infiltration. J Surg Res. 196:130–135. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang X, Lu Y, Feng W, Chen Q, Guo H, Sun X
and Bao Y: A two kinase-gene signature model using CDK2 and PAK4
expression predicts poor outcome in non-small cell lung cancers.
Neoplasma. 63:322–329. 2016.PubMed/NCBI
|
|
35
|
Mao K, Lei D, Zhang H and You C:
MicroRNA-485 inhibits malignant biological behaviour of
glioblastoma cells by directly targeting PAK4. Int J Oncol.
51:1521–1532. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kobayashi K, Inokuchi M, Takagi Y, Otsuki
S, Fujimori Y, Sato Y, Yanaka Y, Higuchi K, Aburatani T, Tomii C,
et al: Prognostic significance of PAK4 expression in gastric
cancer. J Clin Pathol. 69:580–585. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gnad F, Young A, Zhou W, Lyle K, Ong CC,
Stokes MP, Silva JC, Belvin M, Friedman LS, Koeppen H, et al:
Systems-wide analysis of K-Ras, Cdc42, and PAK4 signaling by
quantitative phosphoproteomics. Mol Cell Proteomics. 12:2070–2080.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Siu MK, Chan HY, Kong DS, Wong ES, Wong
OG, Ngan HY, Tam KF, Zhang H, Li Z, Chan QK, et al: p21-activated
kinase 4 regulates ovarian cancer cell proliferation, migration,
and invasion and contributes to poor prognosis in patients. Proc
Natl Acad Sci USA. 107:18622–18627. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ahmed T, Shea K, Masters JR, Jones GE and
Wells CM: A PAK4-LIMK1 pathway drives prostate cancer cell
migration downstream of HGF. Cell Signal. 20:1320–1328. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu W, Yang Y, Liu Y, Liu H, Zhang W, Xu
L, Zhu Y and Xu J: p21-Activated kinase 4 predicts early recurrence
and poor survival in patients with nonmetastatic clear cell renal
cell carcinoma. Urol Oncol. 33:205.e13–e21. 2015. View Article : Google Scholar
|
|
41
|
Abu Aboud O, Chen CH, Senapedis W, Baloglu
E, Argueta C and Weiss RH: Dual and specific inhibition of NAMPT
and PAK4 By KPT-9274 decreases kidney cancer growth. Mol Cancer
Ther. 15:2119–2129. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kesanakurti D, Chetty C, Rajasekhar
Maddirela D, Gujrati M and Rao JS: Functional cooperativity by
direct interaction between PAK4 and MMP-2 in the regulation of
anoikis resistance, migration and invasion in glioma. Cell Death
Dis. 3:e4452012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pan YJ, Wei LL, Wu XJ, Huo FC, Mou J and
Pei DS: miR-106a-5p inhibits the cell migration and invasion of
renal cell carcinoma through targeting PAK5. Cell Death Dis.
8:e31552017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kovacova J, Poprach A, Buchler T, Cho WC
and Slaby O: MicroRNAs as predictive biomarkers of response to
tyrosine kinase inhibitor therapy in metastatic renal cell
carcinoma. Clin Chem Lab Med. 56:1426–1431. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Redova M, Svoboda M and Slaby O: MicroRNAs
and their target gene networks in renal cell carcinoma. Biochem
Biophys Res Commun. 405:153–156. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Al-Ali BM, Ress AL, Gerger A and Pichler
M: MicroRNAs in renal cell carcinoma: Implications for
pathogenesis, diagnosis, prognosis and therapy. Anticancer Res.
32:3727–3732. 2012.PubMed/NCBI
|
|
48
|
Yi C, Wang Q, Wang L, Huang Y, Li L, Liu
L, Zhou X, Xie G, Kang T, Wang H, et al: miR-663, a microRNA
targeting p21(WAF1/CIP1), promotes the proliferation and
tumorigenesis of nasopharyngeal carcinoma. Oncogene. 31:4421–4433.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fiori ME, Villanova L, Barbini C, De
Angelis ML and De Maria R: miR-663 sustains NSCLC by inhibiting
mitochondrial outer membrane permeabilization (MOMP) through
PUMA/BBC3 and BTG2. Cell Death Dis. 9:492018. View Article : Google Scholar : PubMed/NCBI
|
